The review follows years of legal advocacy by Dr. Sunil Aggarwal and represents a critical step toward recognizing psilocybin's therapeutic potential. Schedule I classification currently designates substances as having "no accepted medical use," while Schedule II acknowledges accepted medical applications under strict regulation. If rescheduled to Schedule II, psilocybin would gain federal recognition of its medical value, creating clearer pathways for: Red Light Holland Applauds HHS Review of Psilocybin Re ...